Sign In
Buy SNY
$44.38
+2.01 (+4.74%)
At Close: Jun 04, 2026
Results for Sanofi Spin-Off Good Omen for Sandoz Generics
10:20am, Tuesday, 13'th Sep 2022
Investors might want to take a look at Euroapi S.A. ( XPAR:EAPI , Financial), a Paris-based firm that is a spin-off of Sanofi ( SNY , Financial).
Sanofi: A Nightmarish August To Take Advantage Of
05:00pm, Friday, 09'th Sep 2022
Since 2019, scientific communities have been extensively studying the consequences of the active ingredient ranitidine in ZANTAC, and no evidence of harm to consumers has been found. The first trial i
Sanofi (SNY) Presents at Citi's 17th Annual BioPharma Conference (Transcript)
07:41pm, Wednesday, 07'th Sep 2022
Sanofi (NASDAQ:SNY ) Citi's 17th Annual BioPharma Conference September 7, 2022 2:40 PM ET Company Participants Bill Sibold - EVP, Sanofi Genzyme; President Sanofi NA, Sanofi SA Conference Call Partici
Frederic Oudea to become Sanofi's non-executive chairman
04:24am, Monday, 05'th Sep 2022
The appointment of Societe Generale's boss Frederic Oudea as non-executive chairman of Sanofi will be proposed at the next shareholders meeting of the French drugs group, Sanofi said on Monday.
This Overlooked Danger Could Tank Big Pharma Stocks
06:13pm, Thursday, 01'st Sep 2022
It started out relatively small, or as small as a recall of one of the first drugs to top $1 billion in annual sales can be. In September 2019, individual companies began recalling popular heartburn m
Sanofi (SNY) Hemophilia A Drug BLA Gets FDA Priority Tag
12:47pm, Tuesday, 30'th Aug 2022
Sanofi's (SNY) BLA filing for efanesoctocog alfa was based on data from the XTEND-1 pivotal phase III study.
Analysis-Meagre medicine cabinet leaves Sanofi unloved
12:04am, Monday, 22'nd Aug 2022
Sanofi's recent stock rout underscores the pressure on the French drug maker to redouble its efforts in the hunt for new medicines.
Is Sanofi A Buy, Despite Recent Stumbles?
01:01am, Friday, 19'th Aug 2022
Pharmaceuticals are subject to whiplash trade. That's evident with sharp moves lower in Sanofi, GSK and Teva on news about clinical trials and legal actions.
Sanofi (SNY) Ends Development of Breast Cancer Drug, Stock Down
01:33pm, Wednesday, 17'th Aug 2022
Based on results from a late-stage study, Sanofi (SNY) will discontinue the development of its breast cancer candidate, amcenestrant.
Sanofi trial failure halts work on breast cancer treatment amcenestrant
01:12pm, Wednesday, 17'th Aug 2022
Sanofi has stopped further work on amcenestrant, a treatment once seen to have strong commercial potential in breast cancer, after a second trial failure dealt a major blow to the French healthcare co
Sanofi CFO says stock price pummelling grossly overdone
07:01am, Wednesday, 17'th Aug 2022
Sanofi's finance chief said on Wednesday that a decline in the French company's share price in response to litigation threats and a cancer drug development setback was strongly exaggerated and posed a
Potential Lawsuits Causing Zantac Manufacturers Heartburn
04:10pm, Monday, 15'th Aug 2022
Concerns over potential liability for a medication purported to cause cancer sliced billions off the value of several manufacturers of the drug in the past week. But were the cuts too deep?
PFE, GSK & Other Pharma Stocks Hit by Zantac Litigation
04:33pm, Friday, 12'th Aug 2022
Big pharma stocks, such as Glaxo (GSK), Sanofi (SNY), Pfizer (PFE) and Consumer stock Haleon (HLN), decline due to the litigation surrounding the heartburn drug Zantac (ranitidine).
Pharma companies see sales slump amid ongoing Zantac litigation
04:22pm, Friday, 12'th Aug 2022
Yahoo Finance health care reporter Anjalee Khemlani looks at which pharmaceutical stocks are being affected by litigation surrounding alleged carcinogenic materials in Zantac derivatives.
Drugmaker stocks slammed over Zantac lawsuit concerns
02:20pm, Friday, 12'th Aug 2022
Thousands of lawsuits have been filed against companies including Sanofi, GlaxoSmithKline, Haleon and Pfizer accusing them of failing to properly warn users of the recalled heartburn drugs' health ris
